TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
InnoCan Pharma ( (TSE:INNO) ) just unveiled an announcement.
Innocan Pharma reported its Q3 2025 financial results, showing revenues of $21.6 million, a 10% decrease compared to the previous year. Despite the revenue decline, the company maintained a high gross margin of 90.2% and a stable operating loss. The company continues to advance its LPT-CBD drug delivery platform, with promising pre-clinical results supporting its regulatory strategy. The Consumer Wellness segment demonstrated resilience and profitability despite market challenges, and the company is preparing for a U.S. public offering. These developments position Innocan well for future market recovery and growth.
The most recent analyst rating on (TSE:INNO) stock is a Sell with a C$12.00 price target. To see the full list of analyst forecasts on InnoCan Pharma stock, see the TSE:INNO Stock Forecast page.
Spark’s Take on TSE:INNO Stock
According to Spark, TipRanks’ AI Analyst, TSE:INNO is a Underperform.
InnoCan Pharma’s overall stock score is primarily impacted by its weak financial performance and negative valuation metrics. The technical analysis further highlights a bearish trend, with the stock trading below key moving averages and showing oversold conditions. The absence of earnings call data and corporate events does not alter the negative outlook.
To see Spark’s full report on TSE:INNO stock, click here.
More about InnoCan Pharma
Innocan Pharma is a pharmaceutical company operating in two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, the company focuses on developing innovative drug delivery platform technologies based on advanced cannabinoid science to treat various conditions and improve patients’ quality of life. Their primary drug delivery technology, LPT-CBD, is in the preclinical trial phase for pain management and epilepsy. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative self-care products and holds a 60% stake in BI Sky Global Ltd., which focuses on advanced targeted online sales.
Average Trading Volume: 1,970
Technical Sentiment Signal: Sell
Current Market Cap: C$53.99M
For an in-depth examination of INNO stock, go to TipRanks’ Overview page.